10-Q quarterly report · filed Nov 4, 2026

Nuvation Bio Inc. (NUVB) Q3 2026 10-Q Quarterly Report

Short answer

Nuvation Bio Inc. (NUVB) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $45M (up 242.6% year over year) with net income of −$42M.

Q3 2026 key financials · XBRL

Revenue
$45M
+242.6% YoY · +41.9% QoQ
Net income
−$42M
+24.9% YoY · +33.3% QoQ
Operating margin
-93.9%
EPS (diluted)
−$0.11
+31.3% YoY · +38.9% QoQ

Source: XBRL data from the Nuvation Bio Inc. (NUVB) Q3 2026 10-Q on SEC EDGAR. USD.

Nuvation Bio Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $44.951M, up $31.831M YoY from $13.120M
  • Product revenue $27.457M, up from $7.723M; collaboration revenue $17.494M, up from $5.397M
  • Q3 operating margin -93.9% vs -429.8% YoY, based on total costs and expenses
  • Cash $663.4M at September 30, 2026; operating cash outflow $76.461M for nine months
  • $279.1M net convertible-note proceeds, $58.7M debt repayment, $17.1M capped-call cost; liquidity expected through at least 12 months

Risk Factors

  • Newly added debt risk: $287.5 million of 0.75% Convertible Senior Notes due 2032 issued in July 2026
  • Most material commercialization risk: IBTROZI became the sole FDA-approved product after June 2025 approval, concentrating near-term revenue dependence
  • Regulatory risk: U.S. approval requires pediatric, hepatic impairment, drug interaction and companion-diagnostic post-marketing commitments
  • Operational risk: Single-source taletrectinib API supply while developing a second source
  • Liquidity risk: $663.4 million cash and investments expected to fund operations for at least 12 months, subject to operating-plan assumptions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Nuvation Bio Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.